A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma
-
Published:2024-04
Issue:
Volume:201
Page:113950
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Enzler T.,
Nguyen A.,
Misleh J.,
Cline V.J.,
Johns M.,
Shumway N.,
Paulson S.,
Siegel R.,
Larson T.ORCID,
Messersmith W.ORCID,
Richards D.,
Chaves J.,
Pierce E.ORCID,
Zalupski M.,
Sahai V.ORCID,
Orr D.ORCID,
Ruste S.A.ORCID,
Haun A.,
Kawabe T.